In April 2025, David Allison, CEO of TREAT-NMD, participated in the 2nd General Assembly Meeting of the European Neuromuscular Centre (ENMC) in Hoofddorp, Netherlands. The ENMC is a key organization that facilitates international collaboration and research in the field of neuromuscular disorders. By bringing together scientists, clinicians, and patient organizations, the ENMC plays a vital role in driving progress for rare neuromuscular conditions.
This year’s assembly gathered a wide range of stakeholders—including Executive and Research Committee members, Associated Partners such as the World Duchenne Organization, SMA Europe, and the World Muscle Society, as well as industry leaders like Sanofi, Novartis, Roche, and Amicus Therapeutics.
Participants aligned on strategic priorities for the next two years, with a shared commitment to improving patient care. Key areas of focus include supporting the transition of young patients into adulthood and evaluating long-term outcomes related to gene therapy—both critical challenges in the neuromuscular community.
TREAT-NMD is proud to contribute to this collaborative effort and remains dedicated to improving the lives of those affected by neuromuscular diseases worldwide. If you’re interested in finding out more about the ENMC you can visit their website here.
If you’re interested in collaboration opportunities with TREAT-NMD, please get in touch: info@treat-nmd.com
